SCHEMBL490846

SCHEMBL490846

O=C(OCCc1ccccc1)C(Cc1cccc(O)c1O)C(=O)OCCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.49
ESR1 P03372 2/20 0.44
ESR2 Q92731 1/20 0.44
APP P05067 2/20 0.43
BID P55957 1/20 0.43
BCL2L1 Q07817 1/20 0.43
MCL1 Q07820 1/20 0.43
BAK1 Q16611 1/20 0.43
HCAR2 Q8TDS4 1/20 0.42
TYR P14679 1/20 0.42
AKR1B10 O60218 3/20 0.41
AKR1B1 P15121 3/20 0.41
IAPP P10997 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41
TDP1 Q9NUW8 3/20 0.41
CYP3A4 P08684 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491006 0.89 L3MBTL1 (0.49) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL491102 0.82 APP (0.50) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL490072 0.80 L3MBTL1 (0.62) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL490396 0.80 EGFR (0.55) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL489685 0.80 ALOX5 (0.50) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL490805 0.79 TDP1 (0.61) ALOX5L3MBTL1ESR1ESR2APP
SCHEMBL490722 0.78 CA12 (0.50) L3MBTL1IAPPTDP1MAPK1NPC1
SCHEMBL490685 0.77 KMT2A (0.52) AKR1B1IAPPMMP2MMP9MMP12
SCHEMBL490661 0.76 ABCB1 (0.51) ALOX5ALDH1A1HPGDKDM4E
SCHEMBL490604 0.76 APP (0.64) ALOX5L3MBTL1ESR1ESR2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
EP-2165829-A1 Lithographic printing plate precursor and plate making method thereof Fujifilm Corporation (JP) 2010-03-24 EP disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT ALOX5 180/4885L3MBTL1 4336/4885ESR1 2287/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 ALOX5 905/4885L3MBTL1 3978/4885ESR1 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.